Atezolizumab 加贝伐单抗在 HCC 和 Child-Pugh A 和 B 肝硬化患者中的

StephenW

Atezolizumab 加贝伐单抗在 HCC 和 Child-Pugh A 和 B 肝硬化患者中的安全性和耐受性

肝病学（马里兰州巴尔的摩）

带回家的信息

    这项回顾性研究评估了 atezolizumab 加贝伐单抗 (AtezoBev) 在 HCC 和肝功能受损患者中的安全性和耐受性。这种全身治疗方案是不可切除 HCC 患者的一线选择。评估 Child-Pugh A 和 B 肝硬化患者的治疗相关不良事件 (AE) 以及总生存期和无进展生存期。 Child-Pugh A 和 B 肝硬化患者的治疗相关 AE 发生率相当。中位总生存期为 14.9 个月，Child-Pugh 课程的总缓解率和疾病控制率没有差异。

    研究结果证实了 AtezoBev 在常规临床实践中的安全性和有效性；然而，它需要在 Child-Pugh B 肝硬化患者中进行前瞻性评估。

– Natasha von Roenn，医学博士

StephenW

Safety and Tolerability of Atezolizumab Plus Bevacizumab in Patients With HCC and Child–Pugh A and B Cirrhosis

Hepatology (Baltimore, Md.)

TAKE-HOME MESSAGE

    This retrospective study assessed the safety and tolerability of atezolizumab plus bevacizumab (AtezoBev) in patients with HCC and impaired liver function. This systemic treatment regimen is the first-line option for patients with unresectable HCC. Patients with Child–Pugh A and B cirrhosis were evaluated for treatment-related adverse events (AEs) and overall and progression-free survival. Patients with Child–Pugh A and B cirrhosis had comparable rates of treatment-related AEs. Median overall survival was 14.9 months, and overall response rates and disease control rates did not differ between Child–Pugh classes.

    The findings confirmed the safety and efficacy of AtezoBev in routine clinical practice; however, it needs to be prospectively evaluated in patients with Child–Pugh B cirrhosis.

–  Natasha von Roenn, MD